Search results
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
Zacks via Yahoo Finance· 2 years agoBoston Scientific's (BSX) organic growth performance is strong across all regions where most of its...
Boston Scientific’s cardiac rhythm system hits pivotal trial goals
MedTech Dive via Yahoo Finance· 1 month agoDive Brief: Boston Scientific’s modular cardiac rhythm management system met pre-specified safety...
Boston Scientific (BSX) mCRM System Study Outcome Favorable
Zacks via Yahoo Finance· 1 month agoBoston Scientific Corporation BSX recently presented favorable six-month results from the ongoing...
Boston Scientific hits all endpoints in CRM trial
Medical Device Network via Yahoo Finance· 1 month agoBoston Scientific has announced six-month positive results from its ongoing pivotal MODULAR ATP clinical trial examining the company’s modular cardiac...
Boston Scientific (BSX) Hits 52-Week High: What's Driving It?
Zacks via Yahoo Finance· 1 year agoBoston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and...
Boston Scientific's (BSX) POLARx System Gets FDA Approval
Zacks via Yahoo Finance· 10 months agoBoston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to...
BSX Stock Near Buy Point As Boston Scientific Beats On Earnings, Raises Outlook
Investor's Business Daily· 11 months agoBoston Scientific reported better-than-expected second-quarter financials Thursday, as the medical...
Boston Scientific Yo-Yoes As Medical Recovery Drives Quarterly Beat
Investor's Business Daily· 1 year agoBoston Scientific is benefiting from a rebound in medical procedures, an analyst said Tuesday after...
UPDATE 3-Boston Scientific lifts earnings forecast on solid demand for heart devices
Reuters via Yahoo Finance· 8 months agoBoston Scientific raised its annual profit forecast on Thursday, banking on strong demand for heart devices including its stroke prevention product, Watchman, and a recovery in demand for elective ...
Boston Scientific to buy chronic back pain therapy maker Relievant
Reuters via AOL· 9 months agoThe Massachusetts-based company is also obliged to pay Relievant additional undisclosed payments based on sales performance over the next three years. The deal is the latest in a string of acquisitions ...